The emergence of two microtubule-associated membrane scaffold proteins, STOM and KANK2, as top prioritized potential therapeutic targets for PSP, a primary tauopathy characterized by microtubule-associated protein tau neuropathology, is noteworthy. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.